Market Exclusive

Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events

Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events

Item8.01.Other Events.

On April11, 2017, Agile Therapeutics,Inc. (Agile) issued a press
release announcing that Agile has received the final meeting
minutes from the U.S. Food and Drug Administration (FDA) for its
recent pre-New Drug Application (NDA) submission meeting on its
lead product candidate, Twirla, a once-weekly prescription
contraceptive patch.

A copy of Agiles press release is attached hereto as Exhibit99.1
and is hereby incorporated by reference herein.

Item 9.01. Financial Statements and
Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Agile Therapeutics,Inc. Press Release dated April11, 2017
relating to the results of the Companys pre-New Drug
Application (NDA) submission meeting with the FDA.

About Agile Therapeutics, Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period. Agile Therapeutics, Inc. (NASDAQ:AGRX) Recent Trading Information
Agile Therapeutics, Inc. (NASDAQ:AGRX) closed its last trading session up +0.15 at 3.11 with 172,992 shares trading hands.

Exit mobile version